GlassScriptPhysician profile
Adla D Tessier
NPI 1013915594
$6,465.86
in general payments reported to CMS, 2019-2025
27 companies · $862 in 2025
The $862 reported for 2025 was more than what 83% of Internal Medicine providers received nationally (typical 2025 total: $156).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $1,294 · 2020: $166 · 2021: $3,074 · 2022: $336 · 2023: $392 · 2024: $341 · 2025: $862.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,595.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,594.90 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Echosens North America, INC. | $3,030.00 | 2021 | |
| Gilead Sciences, INC. | $918.23 | 2019-2025 | Vemlidy |
| Madrigal Pharmaceuticals | $444.55 | 2024-2025 | Rezdiffra, Resmetirom |
| Abbvie INC. | $442.12 | 2019-2024 | Mavyret |
| Valeritas, INC. | $282.05 | 2019 | |
| Lilly USA, LLC | $174.35 | 2019-2020 | |
| Novo Nordisk INC | $158.08 | 2019-2025 | Wegovy, Saxenda |
| Edwards Lifesciences Corporation | $149.68 | 2025 | Sapien 3 Ultra Resilia |
| Eisai INC. | $122.81 | 2025 | |
| Astrazeneca Pharmaceuticals LP | $118.81 | 2023 | Imfinzi |
| Novartis Pharmaceuticals Corporation | $113.54 | 2019 | |
| Horizon Therapeutics Plc | $78.44 | 2023 | Actimmune |
| Biocompatibles, INC. | $68.18 | 2019 | |
| Dexcom, INC. | $62.29 | 2023-2024 | Dexcom G6 Transmitter |
| Intercept Pharmaceuticals, INC. | $59.21 | 2022-2024 |
Show all 27 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Merck Sharp & Dohme LLC | $33.99 | 2019 | |
| Orphalan INC | $33.45 | 2023 | Cuvrior |
| Abbott Laboratories | $25.22 | 2025 | Freestyle Libre 3 |
| Dynavax Technologies Corporation | $24.72 | 2019 | |
| Corcept Therapeutics | $22.51 | 2025 | Korlym |
| Ipsen Biopharmaceuticals, INC | $19.60 | 2025 | Iqirvo |
| Mannkind Corporation | $16.54 | 2025 | |
| Mirum Pharmaceuticals, INC. | $15.92 | 2025 | Livmarli |
| Sanofi-Aventis U.S. LLC | $15.60 | 2019 | |
| Pfizer INC. | $12.76 | 2019 | |
| Zealand Pharma US, INC. | $12.16 | 2022 | |
| Phadia US INC. | $11.05 | 2019 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Adla Tessier listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.